Cervical cancer: problem solved? Vaccinating girls against human papillomavirus.
Crosbie
E J
EJ
School of Cancer and Imaging Science, University of Manchester, Manchester, UK. emma.crosbie@manchester.ac.uk
Brabin
L
L
D000293:Adolescent; D002648:Child; D003218:Condylomata Acuminata / Q000191:economics; D003906:Developing Countries; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D008297:Male; D008403:Mass Screening; D032541:Mass Vaccination; D030361:Papillomavirus Infections / Q000150:complications / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000191:economics / Q000627:therapeutic use*; D010342:Patient Acceptance of Health Care / Q000706:statistics & numerical data; D015397:Program Evaluation; D006113:United Kingdom; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D055815:Young Adult; D002578:Uterine Cervical Dysplasia / Q000453:epidemiology / Q000517:prevention & control*
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18